Biodistribution Results of Pretargeting of SK-RC-52 RCC with 111In-/125I-Labeled bs-mAb G250xDTIn-1
| Biodistribution | Group 1 | Group 2 | Group 3 | Group 4 | ||||
|---|---|---|---|---|---|---|---|---|
| 111In—bs-mAb | ||||||||
| Blood | 13.9 ± 1.1 | 12.1 ± 1.3 | 11.6 ± 0.6 | 8.1 ± 1.9 | ||||
| Muscle | 1.4 ± 0.2 | 1.3 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.1 | ||||
| Tumor | 25.7 ± 9.4 | 34.0 ± 10.3 | 32.5 ± 10.8 | 30.0 ± 3.6 | ||||
| Lung | 8.5 ± 0.7 | 6.6 ± 0.5 | 6.6 ± 0.8 | 3.4 ± 0.9 | ||||
| Spleen | 16.9 ± 7.8 | 9.6 ± 4.2 | 6.8 ± 1.7 | 8.0 ± 3.9 | ||||
| Kidney | 5.0 ± 0.5 | 4.2 ± 0.7 | 3.9 ± 0.5 | 3.2 ± 0.5 | ||||
| Liver | 8.4 ± 1.2 | 5.9 ± 0.5 | 7.1 ± 0.9 | 6.0 ± 1.8 | ||||
| Intestine | 5.7 ± 1.5 | 4.5 ± 1.7 | 3.4 ± 0.6 | 3.4 ± 0.7 | ||||
| T/B | 1.9 ± 0.6 | 2.8 ± 0.8 | 2.8 ± 1.0 | 3.8 ± 1.1 | ||||
| 125I—bs-mAb | ||||||||
| Blood | 13.5 ± 2.1 | 12.3 ± 1.4 | 11.8 ± 1.0 | 9.0 ± 1.9 | ||||
| Muscle | 1.6 ± 0.1 | 1.5 ± 0.1 | 1.2 ± 0.1 | 1.0 ± 0.1 | ||||
| Tumor | 14.3 ± 2.1 | 9.9 ± 2.2 | 8.7 ± 2.3 | 7.5 ± 0.7 | ||||
| Lung | 9.2 ± 0.5 | 8.0 ± 2.5 | 6.7 ± 0.4 | 5.2 ± 1.5 | ||||
| Spleen | 6.6 ± 1.7 | 4.3 ± 2.0 | 2.8 ± 0.7 | 2.5 ± 1.0 | ||||
| Kidney | 4.6 ± 0.3 | 4.0 ± 0.5 | 3.4 ± 0.2 | 2.7 ± 0.6 | ||||
| Liver | 3.9 ± 2.2 | 3.6 ± 0.4 | 3.2 ± 0.5 | 2.4 ± 0.6 | ||||
| Intestine | 4.3 ± 0.7 | 3.9 ± 1.0 | 3.0 ± 0.2 | 2.5 ± 0.7 | ||||
| T/B | 1.1 ± 0.04 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.3 | ||||
T/B = tumor-to-blood ratio.
Groups 3 and 4 were injected after 72 h with 6 ng bivalent l-a.a. peptide, loaded with nonlabeled indium.